Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Epidermal Growth Factor Receptor (EGFR) is over-expressed in various solid tumors, correlating with metastatic potential.
• EGFR targeted therapies are crucial in cancer treatment, but imaging agents for EGFR-expressing tumors are needed.

Purpose of the Study:

• To design and characterize the binding specificity of novel anti-EGFR receptor-binding peptidomimetics (AERP) for tumor imaging.
• To evaluate the potential of radiolabeled AERP as a tumor-specific imaging agent.

Main Methods:

• A novel peptidomimetic, AERP, was designed and conjugated to DTPA.
• The conjugate was radiolabeled with Technetium-99m ((99m)Tc).
• In vivo studies assessed tumor accumulation and tumor-to-muscle ratios in A431 xenograft models.

Main Results:

• The radiolabeled peptidomimetic, [(99m)Tc] DTPA-AERP-2, demonstrated in vivo tumor accumulation of 1.6±0.1%ID/g.
• A favorable tumor-to-muscle ratio of 5.5 was achieved.
• Specific binding to EGFR-overexpressing cell lysate and xenograft tumors was observed.

Conclusions:

• The novel peptidomimetic AERP-2 exhibits specific binding to EGFR-expressing tumors.
• [(99m)Tc] DTPA-AERP-2 shows potential as an effective EGFR-specific tumor-imaging agent.
• Further development of AERP-2 is warranted for clinical application in cancer imaging.